Clinical Trial Details
— Status: Suspended
Administrative data
NCT number |
NCT00717652 |
Other study ID # |
ATTGLE0508 |
Secondary ID |
|
Status |
Suspended |
Phase |
Phase 2/Phase 3
|
First received |
|
Last updated |
|
Start date |
July 2008 |
Est. completion date |
July 2008 |
Study information
Verified date |
November 2022 |
Source |
Azidus Brasil |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The objective of this study is evaluating the clinical activity of the association (tretinoin
+ arbutin + triamcinolone) in the treatment of epidermal melasma.
Description:
The melasma is a common hipermelanosis, acquired, symmetrical, with irregular occurring in
areas such as photo-exposed face, forehead and temples, can affect the eyelids and tion. The
facial regions most affected are: zigomatic (82.4%), parotid (64.7%), front (64.7%), mandible
(35.3%) and nasal (35.3%). The injuries of melasma is variable increase of epidermal melanin
and inflammatory infiltrate of mild to moderate intensity. Treatment with compounds such as
hydroquinone and derivatives, tretinoin, corticosteroids moderate or combination of them all
have shown good results, diminishing the training, reducing the stability and promoting the
destruction of melanocytes. The primary objective of this study is evaluating the clinical
activity of the association (tretinoin + arbutin + triamcinolone) manufactured by Glenmark
Laboratory, and as the comparator drug product Triluma ® (hydroquinone + fluocinolone +
tretinoin), in the treatment of epidermal melasma through parameters of clinical course of
the disease (improves) and its security.
Patients who are included in the study will be randomly and automatically receive one of the
treatments (New association or Triluma ®), which should use for 12 weeks. The products should
be applied in the regions affected once a day, during night.
The evaluation of clinical improvement, as well as security, will be held on periodic visits,
as described below, which will be held the record and supply of medicines to patients.
In each visit, beyond the clinical examination of photographs and large, it filled the Area
and Severity Scale (Melasma Area and Severity Index - MASI), which quantifies the melasma and
will be the main tool of control of clinical improvement.
At the end of the study, data will be compared, showing no inferiority or inferiority of
clinical drug testing in relation to the comparator.